Bristol-Myers Squibb Company (BMY)
| Market Cap | 102.27B |
| Revenue (ttm) | 45.53B |
| Net Income (ttm) | -6.15B |
| Shares Out | 2.03B |
| EPS (ttm) | -3.10 |
| PE Ratio | n/a |
| Forward PE | 7.33 |
| Dividend | $2.40 (4.76%) |
| Ex-Dividend Date | Jul 5, 2024 |
| Volume | 31,408,167 |
| Open | 48.27 |
| Previous Close | 45.27 |
| Day's Range | 47.73 - 50.61 |
| 52-Week Range | 39.35 - 63.41 |
| Beta | 0.44 |
| Analysts | Hold |
| Price Target | 57.67 (+14.31%) |
| Earnings Date | Jul 26, 2024 |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esop... [Read more]
Financial Performance
In 2023, BMY's revenue was $45.01 billion, a decrease of -2.50% compared to the previous year's $46.16 billion. Earnings were $8.03 billion, an increase of 26.84%.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for BMY stock is "Hold." The 12-month stock price forecast is $57.67, which is an increase of 14.31% from the latest price.
News
Stocks on the move: Bristol Myers, Abbive, and Tesla
The Investment Committee discuss some of their stocks that are on the move today
Crude Oil Down Over 2%; Bristol Myers Squibb Posts Upbeat Q2 Results
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Friday.
Bristol-Myers Squibb Beats Q2 Expectations, Boosts Guidance on Rising Drug Sales
Bristol-Myers Squibb (BMY) shares climbed Friday after the company beat expectations with its second-quarter results and raised its full-year guidance.
Bristol Myers Stock Jumps. A Sales Jump for Eliquis Boosts Earnings.
Global sales of Eliquis, a drug used to reduce the risk of stroke and blood clots, increase 7% in the second quarter from a year earlier.
Bristol Myers second-quarter results beat expectations, helped by new drugs
Drugmaker Bristol Myers Squibb posted better-than-expected second-quarter results, driven by growth from new products like anemia treatment Reblozyl and heart drug Camzyos as well as from its top-sell...
Bristol Myers Squibb beats earnings estimates, raises outlook as drugmaker slashes costs
Bristol Myers Squibb reported second-quarter earnings and revenue that topped expectations and raised its full-year guidance. Revenue growth was primarily driven by the company's blockbuster blood thi...
Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Reports Second Quarter Financial Results for 2024.
Growth Portfolio Will Likely Drive Bristol Myers Squibb's Q2
Bristol Myers Squibb (NYSE: BMY) is scheduled to report its Q2 2024 results on Friday, July 26. We expect BMY stock to trade higher, with its revenue and earnings likely exceeding the street estimates...
Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--BMS Receives European Medicines Agency Validation of Application for Opdivo plus Yervoy for First-Line Treatment of Unresectable or Advanced HCC.
Bristol-Myers Squibb Reports On 7/26 - Options Expire The Same Day
According to NextEarningsDate.com, the Bristol-Myers Squibb next earnings date is projected to be 7/26 before market open, with earnings estimates of $1.53/share on $10.56 Billion of revenue.
Trade Tracker: Rob Sechan sells Bristol Myers and buys more Abbvie
Rob Sechan, CEO of NewEdge Wealth, joins CNBC's "Halftime Report" to discuss his latest moves. The Committee discuss the Healthcare sector.
Bristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day.
Bristol Myers to pay $2.7 mln to settle Israel anti-competition charges
Bristol Myers Squibb has agreed to pay 10 million shekels ($2.7 million) in Israel to settle a potential case over its blocking of a generic version for anti-cancer drug Imnovid, Israel's Competition ...
Will Bristol Myers Squibb Stock Rebound To Its 2022 Highs Of $80?
Bristol Myers Squibb stock (NYSE: BMY) currently trades at $42 per share, 47% below its pre-inflation shock high of $80 seen in June 2022. In contrast, its peer – Merck stock – is up 56% over this per...
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BristolMyersSquibb--Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients wit...
US FDA approves Bristol Myers' colorectal cancer therapy
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's combination therapy for treating colorectal cancer in patients with a specific gene mutation, the health regulator's website s...
European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BristolMyersSquibb--European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab.
Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024.
Bristol-Myers Squibb stock price forecast: Is the downtrend finally over?
Shares of Bristol-Myers Squibb Co (NYSE:BMY) have had a tumultuous journey since reaching its all-time high above $80 in December 2022. The stock has plummeted by over 50% and now trades in the low $4...
M&A Is Back. 4 Stocks That Could Be Targets.
Mergers and acquisitions are on pace for a solid year. Small-cap biotech and tech look interesting.
Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors.
Bristol Myers Squibb Announces Dividend
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend.
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Augtyro--U.S. FDA Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive.
Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb
Key scientific achievement advances the joint pipeline in the strategic neuroscience partnership with Bristol Myers Squibb and earns a payment of US$ 20 m to Evotec to progress further research HAMBUR...
Why Bristol Myers Squibb Is A Top Socially Responsible Dividend Stock
Bristol Myers Squibb has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 5.8% yield, as w...